Literature DB >> 29194592

Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis.

B Kaplan1, S Golderman1, E Ganelin-Cohen2,3, A Miniovitch4, E Korf5, I Ben-Zvi1,3, A Livneh1,3, S Flechter3,4.   

Abstract

A new procedure was developed and applied to study immunoglobulin free light chains (FLC) in saliva of healthy subjects and patients with multiple sclerosis (MS). The procedure was based on a Western blot analysis for detection and semiquantitative evaluation of monomeric and dimeric FLCs. The FLC indices accounting for the total FLC levels and for the monomer/dimer ratios of κ and λ FLC were calculated, and the cut-off values of the FLC indices were determined to distinguish healthy state from MS disease. The obtained FLC index values were statistically different in the saliva of three groups: active MS patients, MS patients in remission and healthy subjects groups. Our FLC monomer-dimer analysis allowed differentiation between healthy state and active MS with specificity of 100% and a sensitivity of 88·5%. The developed technique may serve as a new non-invasive complementary tool to evaluate the disease state by differentiating active MS from remission with sensitivity of 89% and specificity of 80%.
© 2017 British Society for Immunology.

Entities:  

Keywords:  dimers; immunoglobulin free light chains; monomers; multiple sclerosis; saliva

Mesh:

Substances:

Year:  2017        PMID: 29194592      PMCID: PMC5842412          DOI: 10.1111/cei.13086

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Free light chain monomers in the diagnosis of multiple sclerosis.

Authors:  Batia Kaplan; Boris M Aizenbud; Sizilia Golderman; Regina Yaskariev; Ben-Ami Sela
Journal:  J Neuroimmunol       Date:  2010-09-25       Impact factor: 3.478

2.  Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry.

Authors:  Sophie Desplat-Jégo; Lionel Feuillet; Jean Pelletier; Dominique Bernard; André Ali Chérif; José Boucraut
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

Review 3.  Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases.

Authors:  Marco Thio; Bart R Blokhuis; Frans P Nijkamp; Frank A Redegeld
Journal:  Trends Pharmacol Sci       Date:  2008-03-18       Impact factor: 14.819

4.  Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.

Authors:  Batia Kaplan; Marina Ramirez-Alvarado; Laura Sikkink; Sicilia Golderman; Angela Dispenzieri; Avi Livneh; Gloria Gallo
Journal:  Br J Haematol       Date:  2008-11-29       Impact factor: 6.998

5.  Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion.

Authors:  Gauthier Calais; Gerard Forzy; Charlotte Crinquette; Alexandre Mackowiak; Jerome de Seze; Frederic Blanc; Christine Lebrun; Olivier Heinzlef; Pierre Clavelou; Thibault Moreau; Bernadette Hennache; Helene Zephir; Albert Verier; Véronique Neuville; Christian Confavreux; Patrick Vermersch; Patrick Hautecoeur
Journal:  Mult Scler       Date:  2009-12-22       Impact factor: 6.312

6.  Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study.

Authors:  Stefan Presslauer; Dejan Milosavljevic; Wolfgang Huebl; Fahmy Aboulenein-Djamshidian; Walter Krugluger; Florian Deisenhammer; Makbule Senel; Hayrettin Tumani; Harald Hegen
Journal:  Mult Scler       Date:  2015-07-21       Impact factor: 6.312

7.  Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis.

Authors:  Batia Kaplan; Sizilia Golderman; Gilad Yahalom; Regina Yeskaraev; Tamar Ziv; Boris M Aizenbud; Ben-Ami Sela; Avi Livneh
Journal:  J Immunol Methods       Date:  2013-01-31       Impact factor: 2.303

8.  J chain in malignant human IgG immunocytes.

Authors:  P Brandtzaeg; P Berdal
Journal:  Scand J Immunol       Date:  1975       Impact factor: 3.487

9.  Relationships between levels of lysozyme, lactoferrin, salivary peroxidase, and secretory immunoglobulin A in stimulated parotid saliva.

Authors:  J D Rudney; Q T Smith
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

10.  Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood.

Authors:  Christopher Hohmann; Bianca Milles; Michael Schinke; Michael Schroeter; Jochen Ulzheimer; Peter Kraft; Christoph Kleinschnitz; Paul V Lehmann; Stefanie Kuerten
Journal:  Acta Neuropathol Commun       Date:  2014-09-16       Impact factor: 7.801

View more
  3 in total

1.  Personalized Disease Monitoring in Pediatric Onset Multiple Sclerosis Using the Saliva Free Light Chain Test.

Authors:  Esther Ganelin-Cohen; Evgeny Tartakovsky; Ely Klepfish; Sizilia Golderman; Ayal Rozenberg; Batia Kaplan
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

Review 2.  Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases.

Authors:  Giovanni Schepici; Serena Silvestro; Oriana Trubiani; Placido Bramanti; Emanuela Mazzon
Journal:  Brain Sci       Date:  2020-04-21

Review 3.  The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Kurt-Wolfram Sühs; Hayrettin Tumani; Marie Süße; Thomas Skripuletz
Journal:  Cells       Date:  2021-11-06       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.